ArticleMolecular biology reports2025
Evaluation of the role of circular RNA (circ-FAF1) as a diagnostic biomarker for breast cancer in a cohort of Egyptian breast cancer patients.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Circular RNAs in Plasma and Beyond: Potential Biomarkers for Breast Cancer.Oncology research · 2026Review
- Review
- Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients. METHODS AND
resultsThis case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects. For all study subjects, serum samples were collected for RNA extraction followed by reverse transcription and quantitative real time polymerase chain reaction for circ-FAF1 relative expression level. Serum circ-FAF1 was significantly downregulated in the studied patients compared to control subjects (p < 0.001). Low expression level of circ-FAF1 was significantly associated with presence of lymph node spread (p < 0.001), positive metastasis (p = 0.002), estrogen receptor negativity (p < 0.001), HER2 positivity (p < 0.001), and it was moderately correlated with higher Ki-67 index (r=-0.429, p = 0.001). However, circulating circ-FAF1 level had no statistically significant correlation with progesterone receptor status (p = 0.053), tumor histopathological type (p = 0.895) and histological grade (p = 0.369). Using ROC curve, serum circ-FAF1 had an AUC of 0.885, 81.67% diagnostic sensitivity and 76.67% diagnostic specificity.
conclusionSerum level of circ-FAF1 is a promising biomarker that can help in diagnosis of breast cancer. The low expression in breast cancer was correlated with lymph node spread, presence of metastasis, and with histopathological parameters suggestive of a worse outcome in these patients.
Indexed as
Identifiers
39881045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.